Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

424.53 +4.64 (+1.11%)
Streaming Delayed Price Updated: 2:36 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
67 68 Next >
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
 
Via Benzinga
Nasdaq Correction: The 2 Smartest Stocks to Buy and Hold Forever
Via The Motley Fool
3 Reasons to Avoid VRTX and 1 Stock to Buy Instead
Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%. 
Via StockStory
Topics Stocks
Where Will Vertex Pharmaceuticals Be in 10 Years?
Via The Motley Fool
Which S&P500 stocks are moving on Monday?
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
If I Could Buy Only 1 Growth Stock, This Would Be It
Via The Motley Fool
Is Vertex Pharmaceuticals Gaining or Losing Market Support?
 
Via Benzinga
Analyst Expectations For Vertex Pharmaceuticals's Future
 
Via Benzinga
3 Magnificent Growth Stocks to Buy in March
Via The Motley Fool
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales. 
Via Benzinga
Cannabis For Pain Relief: Scientists Develop New Compound Without Mind-Altering Effects — Alternative To Opioids?
New compound mimics natural molecule in cannabis plant, providing pain relief without addictive side effects. 
Via Benzinga
Topics Cannabis
Good technical signals and a possible breakout for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX).
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) has a strong technical rating of 9 out of 10, indicating a potential breakout. 
Via Chartmill
5 Top Stocks to Buy in March
Via The Motley Fool
Vertex Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results
 
Via Benzinga
Vertex: Strong Sales, Stronger Pipeline
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
 
Via Benzinga
3 Magnificent Growth Stocks to Buy Right Now
Via The Motley Fool
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
Via The Motley Fool
Vertex to Participate in Upcoming March Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Stocks That Could Trounce the Market in 2025
Via The Motley Fool
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
Via The Motley Fool
The Ultimate Healthcare Stock to Buy With $500 Right Now
Via The Motley Fool
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
Via The Motley Fool
Moderna (MRNA) Q4 Earnings Report Preview: What To Look For
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market open. Here’s what to expect. 
Via StockStory
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
Via The Motley Fool
This NXP Semiconductors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
 
Via Benzinga
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.
The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers. 
Via Investor's Business Daily
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for. 
Via StockStory
Vertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays Bullish
The company is betting on strong sales of its cystic fibrosis drugs and early traction from its newly approved non-opioid painkiller. 
Via Stocktwits
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.